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Abstract
Background: In areas endemic for visceral leishmaniasis (VL), a large number of infected individuals mount a protective
cellular immune response and remain asymptomatic carriers. We propose an interferon-gamma release assay (IFN-cRA) as a
novel marker for latent L. donovani infection.
Methods and Findings: We modified a commercial kit (QuantiFERON) evaluating five different leishmania-specific antigens;
H2B, H2B-PSA2, H2B-Lepp12, crude soluble antigen (CSA) and soluble leishmania antigen (SLA) from L. donovani with the
aim to detect the cell-mediated immune response in VL. We evaluated the assay on venous blood samples of active VL
patients (n = 13), cured VL patients (n = 15), non-endemic healthy controls (n = 11) and healthy endemic controls (n = 19).
The assay based on SLA had a sensitivity of 80% (95% CI = 54.81–92.95) and specificity of 100% (95% CI = 74.12–100).
Conclusion: Our findings suggest that a whole-blood SLA-based QuantiFERON assay can be used to measure the cell-
mediated immune response in L. donovani infection. The positive IFN-c response to stimulation with leishmania antigen in
patients with active VL was contradictory to the conventional finding of a non-proliferative antigen-specific response of
peripheral blood mononuclear cells and needs further research.
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Introduction
Visceral leishmaniasis (VL) also known as kala-azar is the most
severe form of leishmaniasis and is a chronic systemic disease that
is fatal unless treated. The main clinical symptoms are an enlarged
spleen and prolonged irregular fever [1]. Approximately 500,000
new cases of human VL occur annually according to WHO
estimations. India, Nepal, Bangladesh, Sudan and Brazil harbour
90% of the worldwide reported VL cases. In 2005 the govern-
ments of India and Bangladesh embarked on a VL elimination
program with the goal to reduce the incidence of disease below 1
per 10 000 per year (TDR 2005).
However, leishmanial infection does not always lead to overt
clinical VL. Leishmanial DNA was detected by PCR in peripheral
blood of subclinically infected patients [2] and promastigotes of
L.infantum can be cultured from the buffy coat of asymptomatically
infected blood donors [3]. The asymptomatic L.donovani carriers
usually outnumber the number of clinical cases, with ratios varying
between 4 to 1 in Bangladesh [4] and 10 to 1 in India and Nepal
[5]. Asymptomatic infected persons were so far never targeted for
treatment, as their role in disease transmission dynamics is poorly
understood, and current drugs are too toxic to justify their use in
otherwise healthy individuals. For the VL elimination initiative it
will be critical though to document the trends in incident L.donovani
infections in the next few years. Typically, serological methods as
Direct Agglutination Test (DAT) and k39 ELISA or leishmanin
skin testing (LST) have been used to document incident infection,
but their respective value as markers of infection has not been
firmly established. Serologic testing is generally assumed to detect
more recent infection, but the length of time for which serology
remains positive, and whether this differs between kala azar
patients and asymptomatically infected individuals (as seems likely
based on the magnitude of the titers), is not known with certainty.
LST is a marker of cell-mediated immunity and remains
positive for many years after the initial infection. Moreover, in VL
cases, LST is known to become negative during the anergic phase
of acute VL, and to return to positive once the cell-mediated
immune response is restored [6]. However, leishmanin antigen is
not well standardized and there is clear variability in sensitivity
and specificity from one antigen to another, and in one study,
there was evidence of loss of antigen potency over time [7,8]. A
previous study found that the sensitivity of LST to detect cell-
mediated immunity in cured VL patients was low in India [9].
Having to read the LST after 48 hrs doesn’t make it a very
practical test for field use. Nevertheless, markers of the cellular
immune response hold promise; T cell proliferation is a possible
outcome of T cell activation and the measurement of IFN-c
released by activated T cells refines assessment of cellular immune
response. In vitro IFN-c release assays (IFN-cRA) (e.g. Quanti-
FERON-TB Gold) have been developed to document latent
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Mycobacterium tuberculosis infection. This assay detects IFN-c in
whole blood stimulated with Mycobacterium tuberculosis specific
peptide antigens with very good sensitivity and specificity
[10,11]. A similar assay based on leishmania antigen(s) might also
be valuable for leishmaniasis. A recent study in Turkey explored
the use of a modified QuantiFERON assay to detect the cell-
mediated immune response against L.infantum [12]. We developed
a novel IFN-cRA based on the QuantiFERON test system and
evaluated its potential to detect L.donovani infection.
Materials and Methods
Study subjects
The study was conducted at Banaras Hindu University,
Varanasi and the Kala-azar Medical Research Centre (KAMRC),
Muzaffarpur, India. The study was approved by the Institutional
Ethics Committee of Banaras Hindu University. Written informed
consent forms were obtained from study subjects. Four different
groups were consecutively recruited: 1) Active VL patients (n = 13);
2) Subjects cured from VL at least six months after the end of
successful treatment (n = 15); 3) Healthy controls living in the
endemic region with no prior history of kala azar (n = 19); and 4)
Non-endemic Healthy Controls having no travel history to Bihar
(n = 11). The inclusion criteria for active VL patients in this study
were the presence of parasite in splenic aspirate confirmed by
microscopy and having related clinical symptoms. The micro-
scopic confirmation of parasite in splenic aspirate was performed
by expert technicians. All cured VL subjects have negative
microscopy at the end of successful treatment. No any clinical
investigation was carried out as the part of this study. The
information about patients’s clinical diagnosis was available at
KAMRC, Muzaffarpur. Subjects having fever history in past one
month and age below 5 years were excluded from the study.
Antigens
QuantiFERON ELISA kits, nil tubes (tubes with no added
antigen) and precoated blood collection tubes with peptides
covering 1) Leish A [H2B peptides], 2) Leish B [peptide pool
of H2B and PSA-2] 3) Leish C [peptide pool of H2B and
Lepp 12] proteins, and Phytohaemagglutinin (PHA) mitogen
tubes were kindly donated by Cellestis limited, Chadstone,
Victoria, Australia. Nil tubes were used for addition of L.donovani
lysates (Crude Soluble Antigen (CSA) and Soluble Leishmania
Antigen (SLA), and Phosphate Buffered Saline (PBS) (no antigen).
H2B has a complete sequence of 111 amino acids. It has 100%
homology with L.infantum, L.major and L.donovani and 80%
homology with L.braziliensis. PSA-2 peptides were from L. major
and L. infantum, and shared 74% homology with L.donovani and
68% with L.tropica. Lepp12 is 88 amino-acid nuclear phosphopro-
tein of L. infantum and has 100% homology with L major and 92%
with L.braziliensis. The H2B and PSA2 peptide antigens were
selected after the initial screening of a series of antigens that
produced requisite sensitivity and specificity in pilot studies
conducted in Turkey [12]. Lepp12 peptides were added to H2B
peptides to investigate its potential in this assay as it has been
described as a highly sensitive and specific antigen for VL [13].
The whole organism antigens were included as controls.
CSA from L. donovani strains was prepared in the Banaras Hindu
University laboratory. Stationary-phase promastigotes (16108
cells/mL) were harvested and centrifuged at 4000 rpm for
20 minutes at 4uC. The pellet so obtained was washed four times
with cold PBS. Pellet was resuspended in PBS containing protease
inhibitors (Sigma) and repeatedly freeze (280uC) thawed 4 times
with each cycle lasting 1–2 hours. In the last cycle, the freezing
was done overnight and then the lysate was thawed, centrifuged at
16000 rpm and supernatant was collected ,and stored in 280uC
until use. Protein estimation was done using bicinonic acid (BCA)
methods.
SLA was prepared as described elsewhere. [14]. Briefly 26109
stationary-phase promastigote were harvested and centrifuged at
4500 rpm for 20 minutes to obtain the pellet. Pellet so obtained
was washed thrice with cold PBS and then resuspended to 10 mM
TRIS-HCl, 1 mM EDTA (pH8.0) 1.6 mM PMSF and 50 mg/mL
leupeptin to obtain a concentration of 26109 parasites/mL. Now
it was sonicated 4–5 times for 15 seconds at 10 Hz and centrifuged
at 270006g for 30 minutes at 4uC. After removing the lipid layer
from the surface of supernatant, remaining solution were
ultracentrifuged at 1000006 g for 4 hrs at 4uC. The supernatant
so obtained was stored at 280uC until use. Protein was estimated
using BCA method. PHA and PBS were used as positive and
negative controls, respectively.
Collection of blood and Interferon-gamma Release Assay
(modified QuantiFERON)
QuantiFERON tubes contain heparin and vacuum to draw
1 ml of venous blood. Blood was collected for each antigen tested
and for positive (PHA) and negative (PBS) controls. Two
additional nil tubes were drawn for addition of SLA and CSA at
a concentration of 4.2 mg/mL and 2.5 mg/mL respectively. After
adding antigens and thoroughly mixing, tubes were incubated
upright in 37uC incubator for 20 hrs without humidity and CO2.
After incubation and centrifugation at 2000 6 g for 10 min,
supernatant plasmas were collected and stored at 220uC for
IFN-c analysis.
Measurement of IFN-c
IFN-c level in proliferated plasma was measured using the
QuantiFERON-ELISA kit using manufacturer’s instructions as
described elsewhere [15]. A 4 point standard curve of known
amount of IFN-c in International Unit per ml (IU/ml) was used to
determine the level of IFN produced in response to different
leishmania antigens. Antigen-specific IFN-c levels (expressed in
IU/mL) produced in response to leishmania antigen stimulation
were determined by subtracting background levels measured in
the non-stimulated (PBS) samples. The calculation and interpre-
Author Summary
Visceral leishmaniasis is caused by a parasite of the
Leishmania species, but infection does not always lead
to overt clinical disease. To detect infection, the Montene-
gro test or Leishmanin Skin Test (LST) is used along with
serological markers. The LST is a test of the delayed-type
hypersensitivity response read 48–72 hours after intrader-
mal injection of leishmanin antigen. LST has many
drawbacks, as complex administration and reading,
boosting of anamnestic immune responses and difficult
sourcing of GMP-compliant product and alternative tools
for epidemiological research are badly needed. We
evaluated whether a Interferon-c Release Assay based on
the QuantiFERON-TB test format, which was approved by
the Food and Drug Administration (FDA) as a test for
detecting latent Mycobacterium tuberculosis infection,
could become an in vitro diagnostic aid for the measure-
ment of cell-mediated immune reactivity against L.dono-
vani. We obtained good results with one of five of the
antigens we evaluated and confirm the potential of this
assay.
IFN-c Release as a Marker of L. donovani Infection
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tation of result was done using software provided by the
manufacturer (Analysis Software v1.51 Cellestis Limited.) as
follows: positive if the IFN-c concentration in either of the antigen
wells was .0.2 IU/mL; this cutoff was determined by ROC
analysis of previous data and selecting the cut-off with highest
sensitivity (83%) and specificity (100%) [12].
Statistical analysis
The Mann-Whitney U-test was used for statistical analysis
between two groups in the IFN-cRA. These statistical analyses
were performed using SPSS software (version 18). Statistical
difference was considered significance if p value was ,0.05. The
sensitivity of the IFN-cRA to detect the cell-mediated immune
response was taken as the percentage positive in the post-treatment
series (cured VL); while specificity was given by 1 minus positivity
in non-endemic healthy control (Table 1).
Results
The number and percentage of subjects yielding positive IFN-c
responses in IFN-cRA assay using 5 different leishmania antigens
for the four study groups are shown in Table 1. All subjects in all
study groups gave positive IFN-c responses after stimulation with
PHA, a non-specific activator of T cells, indicating all subjects
were immunocompetent. The assay was positive after stimulation
with H2B, H2B-PSA2, H2B-Lepp12 peptides, CSA and SLA in
0%, 9%, 18%, 63.6%, and 0% of the non-endemic healthy
controls (n = 11), 10.5%, 21%, 10.5%, 68.4% and 26.3% of
endemic healthy controls (n = 19), 46.6%, 40%, 53.3%, 86.6%
and 80% of the cured subjects (n = 15), and 53.8%, 53.8%, 61.5%,
77.0%, 84.6% of active VL patients (n = 13), respectively. Highest
sensitivity (80% [95% CI= 54.81–92.95]) and specificity (100%
[95% CI= 74.12–100]) for a single antigen preparation was found
using SLA.
The mean IFN-c level against different antigens in the
proliferated blood of four different study groups has been shown
in Figure 1. The mean concentration of IFN-c against SLA
treatment in active VL, cured VL, HEC and NEHC was 5.92, 4.0,
0.35 and 0.02 IU/ml respectively (Figure 1). Twelve of the 15
cured subjects with a history of kala azar showed SLA-specific
IFN-c production. However the SLA specific IFN-c production in
11 of the 13 individuals with active VL disease was a surprising
finding. In order to show IFN-c release was occurring in vitro in
response to SLA, we replaced the plasma of 5 VL subjects with
that of NEHC individuals before treatment with SLA, and
observed again production of IFN-c above basal level (data not
shown).
Discussion
This is the first report on a whole blood Interferon-c release
assay (modified QuantiFERON) as a potential marker of L.donovani
infection. We hope it may contribute to the development of better
markers for infection and to understanding T-cell immune
responses in the high endemic foci of VL in India (Bihar). We
set out to identify an antigen that was highly specific (i.e. not
stimulating any IFN-c release in NEHC individuals who were
never exposed to L.donovani) and maximally stimulated IFN-c
release in whole blood of cured VL patients sampled 6 months
after cure. Among all the antigens tested in the different subject
groups, SLA showed a specificity of 100% as none of the NEHC
subjects were IFN-c positive (Table 1). Leish A and Leish B also
showed good specificity (100% and 91%), however their sensitivity
was low compared to the SLA. CSA showed very low specificity
(36.4%) compared to other antigens. CSA contains the membra-
nous part of the leishmania promastigote which may act as
mitogen leading to positive IFN-c responses in NEHC group.
Lepp12, which is nuclear phosphoprotein of L. infantum, has
previously been described as good marker for diagnosis and
prognosis of VL [13]. In our study Lepp12 showed low sensitivity
and specificity (53% and 82% respectively) and also 10.5% of EC
was IFN-c positive with Lepp12. Its addition to H2B peptides did
not yield major improvement in sensitivity and specificity. A recent
report by Turgay et al [12] found a good sensitivity of a similar
assay with the H2B antigen. However, in Turkey VL is caused by
L.infantum, not L.donovani. The H2B sequence in L.donovani is
homologous with that for L.infantum and hence similar sensitivity to
that obtained in Turkey study was expected in our study. The
apparent lower sensitivity of H2B found in this study may be due
the different length of time between cure and drawing of samples
for IFN-cRA. The cured VL patients in the Turkish study were
sampled 3–17 years after treatment whereas in our study a sample
was taken at 6 months.
This study was designed as a pilot evaluation of a prototype
diagnostic test and used a limited number of purposefully selected
individuals [16], hence further validation is required on a larger
number of subjects. Moreover, an assay detecting 80% of cured
VL patients will not necessarily detect asymptomatic cases with a
distinct cell-mediated immune response with a similar frequency.
A surprising finding in our study was the production of IFN-c in
active VL upon stimulation with leishmanial antigen. Active VL
subjects are immune-suppressed and their Peripheral blood
mononuclear cells (PBMC) don’t proliferate nor give IFN-c
response after leishmania antigen challenge in other studies
[17,18,19]. In our study, all antigens tested showed positive IFN-c
Table 1. Number (%) of subjects with positive IFN-c responses in IFN-c RA using different leishmania antigens.
Study Group Leish A (H2B) Leish B (H2B+ PSA2) Leish C (H2B+ Lepp12) CSA SLA Mitogen
N % N % N % N % N % N %
NEHC (n = 11) 0 0 1 9 2 18 7 63.6 0 0 11 100
Specificity* 100 91 82 36.4 100 -
EHC (n = 19) 2 10.5 4 21 2 10.5 13 68.4 5 26.3 19 100
Active VL(n = 13) 7 53.8 7 53.8 8 61.5 10 77 11 84.6 13 100
Cured VL (n = 15) 7 46.6 6 40 8 53.3 13 86.6 12 80.0 15 100
Sensitivity 46.6 40 53.3 86.6 80.0
NEHC=Non endemic healthy control, VL = Visceral leishmaniasis, EHC= Endemic healthy control.
*Specificity expressed as 1 minus (number positive/n) (%).
doi:10.1371/journal.pntd.0001042.t001
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Figure 1. IFN-c level in Proliferated Blood in different subject groups. IFN-c (IU/mL) production by peripheral blood stimulated with Leish A
(H2B), Leish B (H2B-PSA2), Leish C (H2B-Lepp12) peptides, crude soluble antigen (CSA) and soluble leishmania antigen (SLA) after subtracting the
value of the No Antigen control (PBS) in (A) Non Endemic Healthy Controls (n = 11); (B) Active Visceral leishmaniasis (n = 13); (C) Cured VL , 6 month
after successful treatment (n = 15); (D) Healthy endemic control subjects (n = 19) using whole blood IFN-cRA. Dotted lines represent the assay cutoff
(0.2 IU/mL); (E) Comparison of IFN-c levels (nil value subtracted) for different subject groups using SLA.
doi:10.1371/journal.pntd.0001042.g001
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responses in active VL with highest value observed with the SLA
(84.6%). Even there was IFN- c production after replacement of
plasma (to exclude effect of anti- leishmanial antibodies and
immune-complex mediated production of IFN- c) suggesting that
there was antigen driven IFN- c production in the IFN-cRA. Since
this IFN-cRA approximates the in vivo condition and obviates the
need to purify the mononuclear cells, a possible explanation is that
preparation of PBMCmay remove some factor which has a positive
effect on IFN-c production in active VL.
A valid marker of L.donovani infection is crucial for intervention
studies on vaccine or vector control and for monitoring of ongoing
transmission in endemic areas, and such a tool should moreover be
acceptable, robust and user-friendly. The whole process of test
execution was very simple in the sense that i) venous blood has
been directly collected in the special QuantiFERON collection
tubes, ii) antigens were added in the laboratory and tubes were
incubated at 37uC for 20 hrs, iii) supernatant was collected to
analyse the IFN-c by a one-step commercially available ELISA kit.
So this IFN-cRA assay is as acceptable to the study population as
any other test requiring venous blood draw and is quite simple to
conduct in a regular research laboratory. It has therefore potential
as a marker in future epidemiological research if its validity is
confirmed.
In conclusion, an IFN-cRA based on SLA showed a potential as
marker of L.donovani infection and should be validated further on a
larger series of subjects. Furthermore, the cellular source of IFN-c
released in acute stage VL patients needs to be identified in future
studies.
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